Drug Guidance for Subsidy 02/01/2019 Nintedanib and pirfenidone for treating idiopathic pulmonary fibrosis NRThe Ministry of Health’s Drug Advisory Committee has not recommended listing nintedanib or p... See all × 02/01/2019 Nintedanib and pirfenidone for treating idiopathic pulmonary fibrosis NRThe Ministry of Health’s Drug Advisory Committee has not recommended listing nintedanib or pirfenidone on the Medication Assistance Fund (MAF) for treating idiopathic pulmonary fibrosis, because of limited clinical benefits and unacceptable cost-effectiveness compared with best supportive care at the prices proposed by the manufacturers.
Post Marketing Information DHCPL 26/11/2019 Important safety update on ESBRIET® (pirfenidone) and Drug-Induced Liver Injury (DILI)
General Availability in Public Healthcare Institution Users are to consult the respective PHIs for actual inventory availability and supply restrictions/consideration Tablet, Film Coated 267 mg Singapore General Hospital Tan Tock Seng Hospital Tablet, Film Coated 801 mg Singapore General Hospital Tan Tock Seng Hospital
ORAL Select a brand starting with the letter: E ESBRIET FILM COATED TABLET 267MG [SIN15600P] ESBRIET FILM COATED TABLET 801MG [SIN15601P]